Overview

This open access book is written by world-renowned experts on radiomolecular precision oncology to celebrate the work, life, principles and ideology of Richard P Baum. It includes commentaries, reviews and some thought provoking novel ideas on radionuclide precision oncology, covering topics such as various aspects of theranostics and molecular radiotherapy like radiolabeled peptides, radiolabeled antibodies, dosimetry, and quality control as well as the diagnosis and treatment of specific tumor types. Featuring contributions by biologists, physicists, chemists, mathematicians, geneticists, and physicians from a range of specialties, this Festschrift is highly interdisciplinary and will be a valuable resource for future precision oncologists.  

Full Product Details

Author:   Vikas Prasad
Publisher:   Springer International Publishing AG
Imprint:   Springer International Publishing AG
Edition:   1st ed. 2024
Weight:   0.863kg
ISBN:  

9783031335358

ISBN 10:   303133535
Pages:   380
Publication Date:   06 January 2024
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

"1.            Molecular Radiotherapy: Overcoming resistance; Johannes Czernin 2.            Evolving Role of Nuclear Medicine in Multi-Disciplinary Care at MD Anderson; Homer Macapinlac 3.            Goethe’s Genomic Reflections on Baum - Grau ist alle Theorie; Irvin Modlin 4.            The Lugenium Triptych: Ode to a Theranostics Transcriptome; Lisa Bodei 5.            Theranostics with somatostatin receptor antagonists.; Damian Wild 6.            The times they are a´ changing: Radiometal-theranostics from 86Y/90Y to 68Ga/177Lu and beyond; Frank Rösch 7.            Real-World Evidence: Clinical Outcomes In Precision Radionuclide Oncology. The WARMTH NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer.; J. Harvey Turner 8.            Combining surgery with peptide receptor radionuclide therapy – a step forward in treatment of advanced neuroendocrine tumours; Andrea Frilling 9.            Terbium “Sisters”: More than just a “Swiss Army Knife”; Cristina Müller 10.          'PSMA Radioligand Therapy - A Revolution in the Precision Oncology of Prostate Cancer'; Harshad Kulkarni 11.          Nuclear medicine and surgery a new productive new marriage; Daniel Kämmerer 12.          'Sola dosis facit venenum: Dosimetrie in Precision Oncology with Radiolabelled Probe'; Christiane Schuchardt 13.          Random Walk in Nuclear Medicine - How a Chance Meeting Changed the Course of NET Patient Care in the US; Josh Mailman 14.          Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening & Clinical Translation; Theodosia Maina 15.          Ac-225 PSMA in metastatic prostate cancer without previous chemotherapy; Mike Sathekge 16.          Following the co-evolution of Innovation and demand in the field of precision oncology; Konstantin Zhernosekov, Sebastian Marx 17.          milestone of therapies in NEN; Mariane Pavel 18.          Impact of Radioimmunodetection and Radioimmunotherapy on Theranostics and Antibody-targeted Therapies; David Goldenberg 19.          Molecular imaging platform and radiopharmaceutical transnational research on  Peking University  Cancer Hospital; Zhi Yang 20.          Radioiodine labeled metaiodobenzylguanidine for imaging and treatment of the adrenal medulla and extra-adrenal paraganglia tumors; Manfred Fischer 21.          WARMTH History; Savvas Frangos 22.          How to improve personalised / individualised medicine in 2030; Bertram Wiedenmann 23.          Real Precision Radionuclide Therapy; Ralph  McCready 24.          How do you feel about dosimetry?"" The Gretchenfrage of Radionuclide Therapy; Matthias Blaickner 25.          High-Performance Radiopharmacy - The Base for Precision Oncology; Dirk Müller 26.          The Rise of A Theranostic Empire: Good Governance and Precision Oncology; Vikas Prasad 27.          Peptide Radiochemistry In Precision Oncology Redefined: Integration of Standard Quality Control in GMP Radiochemistry with State of the Art mass Spectrometry; Sonal Prasad 28.          Dose it possible to targeting HER2 using Affibody receptor radionuclide therapy; Hua Zhu 29.          Precision Oncology with PSMA-targeted Alpha Particle Therapy of mCRPC; Jadvar Hossein 30.          18 FDG PET CT assessing Inmunotherapy response; Mariela Agolti 31.          PSMA targeted imaging and therapy with radiolabeled antibodies and peptides; Shankar Vallabhajoshula 32.          Combining targeted radiation therapies in modern clinical oncological practice; Nat Lenzo 33.          From Concept to Clinic and Comercialisation  - Cowboys Wanted; Christian Behrenbruch 34.          Cardiotoxicity of targeted therapies: Imaging of Heart Does Matter; Marcus Hacker 35.          International prostate cancer PSMA RLT trials; Bernd Krause 36.          Fighting for PET in German oncological guidelines and for its reimbursement by Statutory Health Insurances; Dirk Hellwig 37.          CXCR4 Theranostic Experience from India; Baljinder Singh 38.          From Radioimmunodetection to Radiomolecular Precision Oncology via Radionanotargeting  by Intelligent Multidisciplinary Radiotheragnostic Nanoparticles; Kalevi Kairemo 39.          theranostic pair 203Pb and 212Pb for image-guided alpha/beta particle therapy for cancer.; Michael Schultz 40.          Dosing schedule of PSMA: Adaptation in RLT is the key to success against mCRPC; Alexander Haug 41.          Radioiodine labeled metaiodobenzylguanidine for imaging and treatment of the adrenal medulla and extra-adrenal paraganglia tumors; Matthias Schmidt 42.          Theranostics of Hodgkins disease Does it have a future?; John Buscombe 43.          Radioligand Therapy of Thyroid cancer: A Revolution in Evolution; Michael Kreißl 44.          Somatostatin at its receptor the birth of Theranostics; Kjell Öberg 45.          making sure theranostics stays in nuclear medicine; Ken Herrmann 46.          Molecular in-vitro & in-vivo diagnostics as the impartible basis of multimodal therapy approaches in precision oncology; Ralph M Wirtz 47.          precision oncology with radiolabelled compounds"" based on the example : in vitro and in vivo correlation; Maria Athelogou"

Reviews

Author Information

Prof. Dr. Vikas Prasad,  Director Clinical Theranostics, Associate Professor of Radiology Division of Nuclear Medicine, Mallinckrodt Institute of Radiology Washington University in Saint Louis Saint Louis, Missouri, USA

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions